Protara Therapeutics Launches $100M At-The-Market Offering
TARA sits 71% above its 52-week low of $2.77.
Summary
Protara Therapeutics has launched its previously announced At-The-Market (ATM) offering, allowing it to sell up to $100 million of common stock to fund its clinical development programs and general corporate purposes.
Key Events · Financing and Capital Events · TARA
-
At-The-Market Offering Launched
Protara Therapeutics has launched an At-The-Market (ATM) offering, allowing it to sell up to $100,000,000 of common stock from time to time through TD Cowen. This finalizes terms of the offering initiated with the S-3 filing on May 13, 2026.
-
Significant Potential Dilution
The offering represents a potential dilution of approximately 37% of the company's current market capitalization and over 34% of outstanding shares, based on an assumed offering price of $5.21 per share.
-
Use of Proceeds
Net proceeds from the offering are intended to fund the clinical development of TARA-002 and IV Choline Chloride, as well as for working capital and other general corporate purposes.
-
Capital for Clinical Programs
As a clinical-stage biopharmaceutical company with no approved products or product sales revenue, this capital raise is crucial for funding ongoing and future clinical trials for its pipeline candidates.
Analysis · TARA · Life Sciences
This 424B5 filing operationalizes the $100 million At-The-Market (ATM) offering previously registered via an S-3 on May 13, 2026. The company may sell up to $100 million in common stock, which represents a substantial potential dilution of approximately 37% of its current market capitalization and over 34% of outstanding shares. While dilutive, this capital raise is critical for Protara, a clinical-stage biopharmaceutical company, to fund its ongoing and future clinical trials for TARA-002 (in NMIBC and LMs) and IV Choline Chloride, extending its cash runway.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TARA was trading at $4.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $267M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.